Abbott Laboratories reported stronger third quarter 2026 sales and earnings across key segments and outlined plans to spin off its global Nutrition business into a separate public company by the end of 2027.
The company also highlighted progress in its medical devices pipeline, including positive data for the Amulet 360 LAA Occluder and SonicForce Coronary IVL System, reinforcing the role of new products alongside the Nutrition separation.
Next, the focus shifts to how Abbott Laboratories’…
The company also highlighted progress in its medical devices pipeline, including positive data for the Amulet 360 LAA Occluder and SonicForce Coronary IVL System, reinforcing the role of new products alongside the Nutrition separation.
Next, the focus shifts to how Abbott Laboratories’…